Moreover, docetaxel treatment, which is standard chemotherapy for prostate cancer, perpetrated TIS and exacerbated metastasis in TIMP1‐deficient cancer cells, but this reaction could be rescued with ABT‐263, thereby reducing metastatic events [86]. Here, TIMP1 is linked to prostate carcinoma.